p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners

被引:58
作者
Rizos, H [1 ]
Woodruff, S [1 ]
Kefford, RF [1 ]
机构
[1] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia
基金
英国医学研究理事会;
关键词
p14(ARF); sumoylation; hdm2; melanoma;
D O I
10.4161/cc.4.4.1588
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The p14(ARF) tumour suppressor regulates a series of cell cycle regulatory proteins to promote cell cycle arrest in response to abnormal hyperproliferative growth stimuli. p14(ARF) alterations are common in human cancers and, when inherited, confer susceptibility to cutaneous melanoma. We now propose that the mechanism of p14(ARF) action may involve the covalent modification of its binding partners with the small ubiquitin-related protein SUMO-1. In particular, we demonstrate that p14(ARF) interacts with the SUMO E2 conjugating enzyme, Ubc9 and enhances the sumoylation of its binding partners, hdm2, E2F-1, HIF-1 alpha, TBP-1 and p120(E4F). Furthermore, p14(ARF)-induced sumoylation is abrogated by a subset of melanoma-associated p14(ARF) mutations. These results provide a mechanism for p14(ARF) action through a common modification of diverse binding partners.
引用
收藏
页码:597 / 603
页数:7
相关论文
共 59 条
[41]   Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A:: correlation with protein structure information [J].
Ruas, M ;
Brookes, S ;
McDonald, NQ ;
Peters, G .
ONCOGENE, 1999, 18 (39) :5423-5434
[42]   PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies [J].
Sachdev, S ;
Bruhn, L ;
Sieber, H ;
Pichler, A ;
Melchior, F ;
Grosschedl, R .
GENES & DEVELOPMENT, 2001, 15 (23) :3088-3103
[43]   p53 is involved in the p120E4F-mediated growth arrest [J].
Sandy, P ;
Gostissa, M ;
Fogal, V ;
De Cecco, L ;
Szalay, K ;
Rooney, RJ ;
Schneider, C ;
Del Sal, G .
ONCOGENE, 2000, 19 (02) :188-199
[44]   Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity [J].
Schmidt, D ;
Müller, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) :2872-2877
[45]  
Sherr CJ, 2004, CELL CYCLE, V3, P239
[46]  
SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO
[47]  
2-9
[48]   Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France [J].
Soufir, N ;
Avril, MF ;
Chompret, A ;
Demenais, F ;
Bombled, J ;
Spatz, A ;
Stoppa-Lyonnet, D ;
Bénard, J ;
Bressac-de Paillerets, B .
HUMAN MOLECULAR GENETICS, 1998, 7 (02) :209-216
[49]   The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 [J].
Stott, FJ ;
Bates, S ;
James, MC ;
McConnell, BB ;
Starborg, M ;
Brookes, S ;
Palmero, I ;
Ryan, K ;
Hara, E ;
Vousden, KH ;
Peters, G .
EMBO JOURNAL, 1998, 17 (17) :5001-5014
[50]   Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing [J].
Sugimoto, M ;
Kuo, ML ;
Roussel, MF ;
Sherr, CJ .
MOLECULAR CELL, 2003, 11 (02) :415-424